Upregulation of HERV-K (HML-2) in hepatocellular carcinoma patients was significantly related to cancer progression and poor outcome, indicating that HERV-K (HML-2) might be a novel candidate prognostic biomarker for hepatocellular carcinoma (Ma et al., 2016). This evidence concerns the gene CLEC10A and cancer.